Secondly, given the dearth of immunotherapy data in the existing retrospective osteosarcoma cohort, further collection of information on osteosarcoma patients treated with ICB, including age, gender, genetic polymorphisms, tumor antigenicity, MHC antigen expression, the function of interferon signaling pathways, and oncogenic signaling pathways, may prove beneficial in exploring the potential value of the HSPscore in predicting the sensitivity to ICB treatment. The gene discussed is HLA-C; the disease is osteosarcoma.